MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale
Expert Review of Anti-infective Therapy, 2021•Taylor & Francis
Introduction COVID-19 disease progresses through a number of distinct phases. The
management of each phase is unique and specific. The pulmonary phase of COVID-19 is
characterized by an organizing pneumonia with profound immune dysregulation, activation
of clotting, and a severe microvascular injury culminating in severe hypoxemia. The core
treatment strategy to manage the pulmonary phase includes the combination of
methylprednisolone, ascorbic acid, thiamine, and heparin (MATH+ protocol). The rationale …
management of each phase is unique and specific. The pulmonary phase of COVID-19 is
characterized by an organizing pneumonia with profound immune dysregulation, activation
of clotting, and a severe microvascular injury culminating in severe hypoxemia. The core
treatment strategy to manage the pulmonary phase includes the combination of
methylprednisolone, ascorbic acid, thiamine, and heparin (MATH+ protocol). The rationale …
Introduction
COVID-19 disease progresses through a number of distinct phases. The management of each phase is unique and specific. The pulmonary phase of COVID-19 is characterized by an organizing pneumonia with profound immune dysregulation, activation of clotting, and a severe microvascular injury culminating in severe hypoxemia. The core treatment strategy to manage the pulmonary phase includes the combination of methylprednisolone, ascorbic acid, thiamine, and heparin (MATH+ protocol). The rationale for the MATH+ protocol is reviewed in this paper.
Areas covered
We provide an overview on the pathophysiological changes occurring in patients with COVID-19 respiratory failure and a treatment strategy to reverse these changes thereby preventing progressive lung injury and death.
Expert opinion
While there is no single ‘Silver Bullet’ to cure COVID-19, we believe that the severely disturbed pathological processes leading to respiratory failure in patients with COVID-19 organizing pneumonia will respond to the combination of Methylprednisone, Ascorbic acid, Thiamine, and full anticoagulation with Heparin (MATH+ protocol).We believe that it is no longer ethically acceptable to limit management to ‘supportive care’ alone, in the face of effective, safe, and inexpensive medications that can effectively treat this disease and thereby reduce the risk of complications and death.
Taylor & Francis Online